MEG - CNBC

search results for

refine results

sort by

Date
Relevance

result type

Articles
Video

Wires
Press Releases

Mixed bag for biotech earnings

CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.

Source: CNBC.com

Vertex Pharma earnings beat $0.41 vs. $0.39 est.

CNBC's Meg Tirrell reports Vertex Pharmaceuticals' quarterly earnings.

Source: CNBC.com

Biopharma earnings bonanza

CNBC's Meg Tirrell reports on the moves in the biotech sector following earnings from Amgen, Bristol-Myers and more. The "Fast Money Halftime Report" traders weigh in.

Source: CNBC.com

Amgen CEO: Hopeful Trump administration can deliver tax reform

CNBC's Meg Tirrell reports on the after-hours action for Amegen, including what chairman and CEO Robert Bradway had to say on the conference call. The "Fast Money" traders weigh in.

Source: CNBC.com

Amgen EPS beats, revenues miss

Earnings are out for Amgen. CNBC's Meg Tirrell reports the details.

Source: CNBC.com

Express Scripts CEO on Anthem contract: Time to show investors power in our core

Express Scripts CEO Tim Wentworth speaks to CNBC's Meg Tirrell about Q1 earnings and the company's contract with Anthem.

Source: CNBC.com

Express Scripts provides update on Anthem partnership

Earnings are out for Express Scripts. CNBC's Meg Tirrell reports the details.

Source: CNBC.com

Behind the $24 billion medical device deal

CNBC's Meg Tirrell reports the latest on the deal between Becton Dickinson and C.R. Bard.

Source: CNBC.com

Drug companies risk Trump's wrath as they march for science

This Saturday's March for Science is trying hard to be a nonpartisan event, but some may not see it that way.

Source: CNBC.com

What to expect from biotech

CNBC's Meg Tirrell discusses what healthcare investors should expect from the biotech sector. With the "Fast Money" traders.

Source: CNBC.com